Health & Medicine
A new antifungal drug works in a surprising way
Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.
Humans
We summarize the week's science breakthroughs every Thursday.
More Stories in Humans
- Microbes
Elite athletes’ poop may hold clues to boosting metabolism
In a small study, mice given fecal transplants from elite cyclists and soccer players had higher levels of glycogen, a key energy source.
- Health & Medicine
Surgeons transplanted a pig’s liver into a human
A genetically modified mini pig’s liver was able to function in the body of a brain-dead patient throughout a 10-day experiment.
- Genetics
What 23andMe’s bankruptcy means for your genetic data
As 23andMe prepares to be sold, Science News spoke with two experts about what’s at stake and whether consumers should delete their genetic data.
- Animals
You might be reading your dog’s moods wrong
A dog's physical cues often take a back seat to environmental ones, skewing humans' perceptions, a small study suggests.
- Health & Medicine
Tuberculosis could be eradicated. So why isn’t it?
John Green’s new book, Everything Is Tuberculosis, reveals how social injustice sustains the disease, despite available cures and vaccines.
- Health & Medicine
Avoidable deaths increased in the U.S. as they dropped elsewhere
In the United States, deaths that could have been avoided rose, on average, from 2009 to 2019. That’s in contrast to European Union countries.
- Health & Medicine
A deep brain stimulation volunteer discusses life after depression
In this bonus episode of The Deep End, you’ll hear an update from Jon Nelson, who is living what he calls his "bonus life."
- Neuroscience
Human memory is flawed. But a new book says that’s OK
The new book Memory Lane convincingly demonstrates how memories are like Lego buildings that are constantly being rebuilt.
- Health & Medicine
An mRNA cancer vaccine may offer long-term protection
A vaccine kept patients free of pancreatic cancer for years, yet new reports say the NIH is advising against mentioning mRNA tech in grants.
